Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation
Published on: October 11, 2024
Ethics of Placebo Control in Trials for Idiopathic Sudden Sensorineural Hearing Loss
Miguel Maldonado Fernández1, Susan Kornetsky2, Laura Rubio Rodriguez3
1ENT Department, Hospital Vital Alvarez-Buylla, Mieres, Spain Maldonado2000@gmail.com.
Abstract:
Idiopathic sudden sensorineural hearing loss (ISSHL) involves sudden loss of hearing from cochlear or retrocochlear origin of unknown cause. Systemic corticosteroids may be considered in the management of ISSNHL. However, an updated Cochrane systematic review concludes that "the value of steroids in the treatment of idiopathic sudden sensorineural hearing loss remains unclear since the evidence obtained from randomized controlled trials is contradictory in outcome." Therefore, a new clinical trial that addresses this question is mandatory. A first step in its design is to determine if placebo control would be ethically acceptable. We conclude that there is equipoise (uncertainty) about the use of corticosteroids for ISSHL. A new trial is justified-but with the inclusion of interim analyses to detect early imbalances on efficacy or safety and with the ability to stop the trial if needed.
Related Concept Videos
The Placebo Effect
Hearing
Ethics in Research
Line Loss
Line loss impacts power delivery efficiency in a balanced three-phase circuit. The symmetry in such a circuit simplifies the...
Ethics and Bioethics
Ethical Issues
Ethical Concerns in Healthcare:

